Literature DB >> 32651801

Regadenoson versus dipyridamole: Evaluation of stress myocardial blood flow response on a CZT-SPECT camera.

Quentin Brana1,2, Frédérique Thibault1, Maxime Courtehoux2, Gilles Metrard1, Maria Joao Ribeiro2, Denis Angoulvant3, Matthieu Bailly4.   

Abstract

BACKGROUND: Regadenoson is a selective adenosine receptor agonist. It is currently unclear if the level of hyperemia differs between stress agents. We compared Myocardial Blood Flow (MBF) and Myocardial Flow Reserve (MFR) response on CZT-SPECT Myocardial Perfusion Imaging (MPI) to evaluate if dipyridamole and regadenoson could induce the same level of hyperemia.
METHODS: 228 patients with dynamic CZT-SPECT MPI were retrospectively analyzed (66 patients stressed with regadenoson and 162 with dipyridamole) in terms of MBF and MFR. To rule out confounding factors, two groups of 41 patients were matched for clinical characteristics in a sub-analysis, excluding high cardiovascular risk patients.
RESULTS: Overall stress MBF was higher in regadenoson patients (1.71 ± 0.73 vs. 1.44 ± 0.55 mL·min-1·g-1 for regadenoson and dipyridamole, respectively, p < .05). However, when confounding factors were ruled out, stress MBF (1.57 ± 0.56 vs. 1.61 ± 0.62 mL·min-1·g-1 for dipyridamole and regadenoson, respectively, p = .88) and MFR (2.62 ± 0.77 vs. 2.46 ± 0.76 for dipyridamole and regadenoson, respectively, p = .40) were not different between regadenoson and dipyridamole.
CONCLUSIONS: Our results suggest that dipyridamole and regadenoson induce equivalent hyperemia in dynamic SPECT with similar stress MBF and MFR in comparable patients.
© 2020. American Society of Nuclear Cardiology.

Entities:  

Keywords:  CZT-SPECT; Dipyridamole; Myocardial blood flow; Myocardial flow reserve; Regadenoson

Mesh:

Substances:

Year:  2020        PMID: 32651801     DOI: 10.1007/s12350-020-02271-5

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  46 in total

1.  Seizures associated with regadenoson: a case series.

Authors:  Robert Lee Page; Patrice Spurck; Jacquelyn L Bainbridge; Julie Michalek; Robert A Quaife
Journal:  J Nucl Cardiol       Date:  2012-04       Impact factor: 5.952

Review 2.  Advances in pharmacologic stress agents: focus on regadenoson.

Authors:  Sara G Johnson; Scott Peters
Journal:  J Nucl Med Technol       Date:  2010-08-19

Review 3.  Current advances in vasodilator pharmacological stress perfusion imaging.

Authors:  Regina S Druz
Journal:  Semin Nucl Med       Date:  2009-05       Impact factor: 4.446

4.  Comparison of the prognostic value of normal regadenoson with normal adenosine myocardial perfusion imaging with propensity score matching.

Authors:  Fahad M Iqbal; Fadi G Hage; Ali Ahmed; Phillip J Dean; Saleem Raslan; Jaekyeong Heo; Ami E Iskandrian
Journal:  JACC Cardiovasc Imaging       Date:  2012-10

5.  Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial.

Authors:  Ami E Iskandrian; Timothy M Bateman; Luiz Belardinelli; Brent Blackburn; Manuel D Cerqueira; Robert C Hendel; Hsiao Lieu; John J Mahmarian; Ann Olmsted; S Richard Underwood; João Vitola; Whedy Wang
Journal:  J Nucl Cardiol       Date:  2007 Sep-Oct       Impact factor: 5.952

6.  Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.

Authors:  Manuel D Cerqueira; Patricia Nguyen; Peter Staehr; S Richard Underwood; Ami E Iskandrian
Journal:  JACC Cardiovasc Imaging       Date:  2008-05

7.  Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial.

Authors:  Brian R Leaker; B O'Connor; Trevor T Hansel; Peter J Barnes; Lixen Meng; Vandana S Mathur; Hsiao D Lieu
Journal:  J Nucl Cardiol       Date:  2008-04-14       Impact factor: 5.952

8.  Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial.

Authors:  John J Mahmarian; Manuel D Cerqueira; Ami E Iskandrian; Timothy M Bateman; Gregory S Thomas; Robert C Hendel; Lemuel A Moye; Ann W Olmsted
Journal:  JACC Cardiovasc Imaging       Date:  2009-08

9.  Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: a quantitative analysis from the ADVANCE MPI trials.

Authors:  John J Mahmarian; Leif E Peterson; Jiaqiong Xu; Manuel D Cerqueira; Ami E Iskandrian; Timothy M Bateman; Gregory S Thomas; Faisal Nabi
Journal:  J Nucl Cardiol       Date:  2014-10-07       Impact factor: 5.952

Review 10.  Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge.

Authors:  Yasmeen Golzar; Rami Doukky
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-01-22
View more
  7 in total

1.  Myocardial blood flow is the dominant factor influencing cardiac magnetic resonance adenosine stress T2.

Authors:  Jill J Weyers; Venkat Ramanan; Ahsan Javed; Jennifer Barry; Melissa Larsen; Krishna Nayak; Graham A Wright; Nilesh R Ghugre
Journal:  NMR Biomed       Date:  2021-11-17       Impact factor: 4.044

2.  High technology by CZT cameras: It is time to join forces.

Authors:  Adriana D'Antonio; Roberta Assante; Emilia Zampella; Wanda Acampa
Journal:  J Nucl Cardiol       Date:  2021-08-23       Impact factor: 3.872

3.  Myocardial flow reserve estimation with contemporary CZT-SPECT and 99mTc-tracers lacks precision for routine clinical application.

Authors:  Edward P Ficaro; Venkatesh L Murthy; Jennifer M Renaud; Alexis Poitrasson-Rivière; Tomoe Hagio; Jonathan B Moody; Liliana Arida-Moody
Journal:  J Nucl Cardiol       Date:  2021-08-23       Impact factor: 3.872

Review 4.  Expanding the repertoire of methanocarba nucleosides from purinergic signaling to diverse targets.

Authors:  Kenneth A Jacobson; Veronica Salmaso; R Rama Suresh; Dilip K Tosh
Journal:  RSC Med Chem       Date:  2021-07-13

5.  Regadenoson versus dipyridamole: Evaluation of stress myocardial blood flow response on a CZT-SPECT camera.

Authors:  Quentin Brana; Frédérique Thibault; Maxime Courtehoux; Gilles Metrard; Maria Joao Ribeiro; Denis Angoulvant; Matthieu Bailly
Journal:  J Nucl Cardiol       Date:  2020-07-10       Impact factor: 5.952

Review 6.  Quantitative clinical nuclear cardiology, part 2: Evolving/emerging applications.

Authors:  Piotr J Slomka; Jonathan B Moody; Robert J H Miller; Jennifer M Renaud; Edward P Ficaro; Ernest V Garcia
Journal:  J Nucl Cardiol       Date:  2020-10-16       Impact factor: 5.952

7.  Myocardial Flow Reserve Measurement During CZT-SPECT Perfusion Imaging for Coronary Artery Disease Screening: Correlation With Clinical Findings and Invasive Coronary Angiography-The CFR-OR Study.

Authors:  Matthieu Bailly; Frédérique Thibault; Maxime Courtehoux; Gilles Metrard; Denis Angoulvant; Maria Joao Ribeiro
Journal:  Front Med (Lausanne)       Date:  2021-06-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.